Detalhe da pesquisa
1.
Activating alleles of JAK3 in acute megakaryoblastic leukemia.
Cancer Cell
; 10(1): 65-75, 2006 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-16843266
2.
Constitutive JAK3 activation induces lymphoproliferative syndromes in murine bone marrow transplantation models.
Blood
; 113(12): 2746-54, 2009 Mar 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-19139084
3.
The OTT-MAL fusion oncogene activates RBPJ-mediated transcription and induces acute megakaryoblastic leukemia in a knockin mouse model.
J Clin Invest
; 119(4): 852-64, 2009 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-19287095
4.
Notch signaling specifies megakaryocyte development from hematopoietic stem cells.
Cell Stem Cell
; 3(3): 314-26, 2008 Sep 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-18786418
5.
Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera.
Cancer Cell
; 13(4): 311-20, 2008 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-18394554
6.
JAK2T875N is a novel activating mutation that results in myeloproliferative disease with features of megakaryoblastic leukemia in a murine bone marrow transplantation model.
Blood
; 108(8): 2770-9, 2006 Oct 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-16804112
7.
The small molecule tyrosine kinase inhibitor AMN107 inhibits TEL-PDGFRbeta and FIP1L1-PDGFRalpha in vitro and in vivo.
Blood
; 106(9): 3206-13, 2005 Nov 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-16030188